Scholarlink

<p>Endothelial dysfunction is a hallmark of diabetes, primarily driven by fluctuating blood glucose levels that contribute to vascular complications. Epigenetic regulation through histone modifications plays a crucial role in mediating such pathological gene expression changes. This study delineates the differential acetylation pattern of histone H4 lysine residues in endothelial cells exposed to intermittent high glucose (IHG) conditions. IHG treatment led to a significant deacetylation of H4K5 and H4K16 residues, whereas acetylation at H4K8 and H4K12 remained unaltered. Consistently, streptozotocin (STZ)-induced diabetic rats exhibited reduced H4K5 acetylation specifically in the glomerular endothelium after six&#xa0;weeks of hyperglycemia. Mechanistically, human umbilical vein endothelial cells (HUVECs), human glomerular endothelial cells (HGECs) and EA.hy926 cells demonstrated a marked upregulation of histone deacetylase 1 (HDAC1) under IHG conditions, which was corroborated by elevated expression of ICAM1, p21 and reduced eNOS and KLF2. Furthermore, we also observed an increased HDAC1 expression in diabetic rat glomeruli. Among histone acetyl transferases (HATs) specific to H4K5Ac, KAT7, KAT6A, and p300 were elevated, while PCAF showed a reduction under IHG stress. Furthermore, chromatin immunoprecipitation (ChIP)-qPCR analysis revealed a loss of H4K5 acetylation enrichment on the promoters of <i>KLF2</i> and <i>eNOS</i> under IHG. Notably, pharmacological inhibition of HDAC1 with pyroxamide or gene silencing via siRNA restored H4K5 acetylation levels. Functionally, IHG exposure suppressed endothelial nitric oxide synthase (eNOS) and its transcriptional regulator KLF2, whereas HDAC1 inhibition reinstated their expression, suggesting epigenetic restoration of endothelial homeostasis. We also observed a reversal in the ICAM1 expression upon pyroxamide treatment, which was functionally characterized by the reduced THP1 cell binding to HUVEC exposed to IHG along with pyroxamide. Collectively, our findings uncover a previously unrecognized histone H4-driven mechanism governing endothelial dysfunction in diabetes, wherein HDAC1-mediated H4K5 deacetylation represses <i>KLF2</i>-<i>eNOS</i> signaling. Targeting HDAC1 thus presents a promising therapeutic approach for mitigating vascular complications associated with diabetes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Histone H4K5 deacetylation by enhanced HDAC1 expression drives endothelial inflammation in diabetes through repression of the KLF2-eNOS axis

  • 期刊论文

  • 发表日期：

    2026年5月28日

查看全文
  • Srinjoy Chakraborty,
  • Vivek Akhouri,
  • Yash Tushar Katakia,
  • Shyam Kumar Ramakrishnan,
  • Anil Bhanudas Gaikwad,
  • Syamantak Majumder

摘要

Endothelial dysfunction is a hallmark of diabetes, primarily driven by fluctuating blood glucose levels that contribute to vascular complications. Epigenetic regulation through histone modifications plays a crucial role in mediating such pathological gene expression changes. This study delineates the differential acetylation pattern of histone H4 lysine residues in endothelial cells exposed to intermittent high glucose (IHG) conditions. IHG treatment led to a significant deacetylation of H4K5 and H4K16 residues, whereas acetylation at H4K8 and H4K12 remained unaltered. Consistently, streptozotocin (STZ)-induced diabetic rats exhibited reduced H4K5 acetylation specifically in the glomerular endothelium after six weeks of hyperglycemia. Mechanistically, human umbilical vein endothelial cells (HUVECs), human glomerular endothelial cells (HGECs) and EA.hy926 cells demonstrated a marked upregulation of histone deacetylase 1 (HDAC1) under IHG conditions, which was corroborated by elevated expression of ICAM1, p21 and reduced eNOS and KLF2. Furthermore, we also observed an increased HDAC1 expression in diabetic rat glomeruli. Among histone acetyl transferases (HATs) specific to H4K5Ac, KAT7, KAT6A, and p300 were elevated, while PCAF showed a reduction under IHG stress. Furthermore, chromatin immunoprecipitation (ChIP)-qPCR analysis revealed a loss of H4K5 acetylation enrichment on the promoters of KLF2 and eNOS under IHG. Notably, pharmacological inhibition of HDAC1 with pyroxamide or gene silencing via siRNA restored H4K5 acetylation levels. Functionally, IHG exposure suppressed endothelial nitric oxide synthase (eNOS) and its transcriptional regulator KLF2, whereas HDAC1 inhibition reinstated their expression, suggesting epigenetic restoration of endothelial homeostasis. We also observed a reversal in the ICAM1 expression upon pyroxamide treatment, which was functionally characterized by the reduced THP1 cell binding to HUVEC exposed to IHG along with pyroxamide. Collectively, our findings uncover a previously unrecognized histone H4-driven mechanism governing endothelial dysfunction in diabetes, wherein HDAC1-mediated H4K5 deacetylation represses KLF2-eNOS signaling. Targeting HDAC1 thus presents a promising therapeutic approach for mitigating vascular complications associated with diabetes.